CDEK
← All drugs Report issue

elx-02

Small moleculeexperimental

Clinical trial activity

8 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Aug 1, 2016 (NCT02807961)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C[C@@H](N)[C@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]3O[C@H]([C@@H](C)O)[C@@H](O)[C@H](O)[C@H]3N)[C@H](O)[C@@H]1O
Mol. weight
482.5258 g/mol
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • elx-02

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05448755Phase 2Nov 28, 2022Eloxx Pharmaceuticals, Inc.
NCT04135495Phase 2Oct 16, 2019Eloxx Pharmaceuticals, Inc.
NCT04126473Phase 2Oct 10, 2019Eloxx Pharmaceuticals, Inc.
NCT04069260Phase 2Aug 31, 2019Eloxx Pharmaceuticals, Inc., McGill University
NCT03776539Phase 1Jan 4, 2019Eloxx Pharmaceuticals, Inc., Syneos Health
NCT03309605Phase 1Oct 11, 2017Eloxx Pharmaceuticals, Inc., SGS Life Sciences
NCT03292302Phase 1Sep 26, 2017Eloxx Pharmaceuticals, Inc., SGS Life Sciences
NCT02807961Phase 1Aug 1, 2016Cato Research, Eloxx Pharmaceuticals, Inc.
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Eloxx Pharmaceuticals, Inc.For profit8822016
SGS Life SciencesFor profit2012017
Cato ResearchFor profit1012016
McGill UniversityAcademic/Hospital1012019
Syneos HealthFor profit1012019
5 organizations
Page 1 / 1